Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Progression of Myopia in Children and Adolescents in a Randomized, Double-blind, Placebo Parallel-controlled, Multicenter, Phase III Clinical Trial

NCT06708156 is registered in ClinicalTrials.gov with Oupushifang Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06708156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06708156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Progression of Myopia in Children and Adolescents in a Randomized, Double-blind, Placebo Parallel-controlled, Multicenter, Phase III Clinical Trial
Lead sponsor
Oupushifang Pharmaceutical Technology Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
June 15, 2024
Completion date
December 31, 2027
Enrollment
606 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

myopia, myopia progression